Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01556126Not ApplicableCompleted

Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population

Role: lead

NCT03510676Not ApplicableCompleted

The ILLUMINA Study. (ILLUMINA)

Role: lead

NCT01122719Not ApplicableTerminated

Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen

Role: lead

NCT00920283Not ApplicableCompleted

COMPETE: A Clinical Evaluation of Chrono Carbostent Carbofilm™ Coated Stent

Role: lead

NCT01543373Not ApplicableCompleted

Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS

Role: lead

NCT01373502Not ApplicableCompleted

International Randomized Comparison Between DES Limus Carbostent and Taxus DES in the Treatment of De-novo Coronary Lesions

Role: lead

All 6 trials loaded